Methotrexate Recommendations for Systemic Autoimmune Rheumatic Disease‑Associated Interstitial Lung Disease

Guideline Recommendations

• The 2023 ACR/CHEST guideline conditionally recommends against initiating methotrexate as first‑line therapy for SARD‑ILD because of insufficient efficacy data. 1
• The same guideline conditionally recommends continuing methotrexate in patients who are already receiving it for joint disease when ILD is mild and stable, rather than switching to an alternative DMARD. 1

Evidence Supporting Continuation

• Observational studies cited by the ACR/CHEST guideline indicate that methotrexate is not associated with progression of pre‑existing ILD. 1
• A 2021 case‑control study found that methotrexate ever‑users were less common among RA‑ILD patients (adjusted OR 0.43) and that ILD detection was delayed in methotrexate users (median 11.4 years vs 4.0 years), suggesting a protective or neutral effect on lung disease onset. 1

Safety and Monitoring

Immediate Stopping Criteria

• Discontinue methotrexate immediately if methotrexate pneumonitis is suspected (acute/sub‑acute cough, dyspnea, fever). 1
• Discontinue methotrexate if ILD develops or progresses while the drug is being used. 1
• Discontinue methotrexate if the patient develops respiratory symptoms suggestive of drug toxicity. 2

High‑Risk Features for Pneumonitis

• Pre‑existing lung disease, current cigarette smoking, and age > 40 years are documented risk factors that markedly increase the likelihood of methotrexate‑related pneumonitis. 2

Pre‑Treatment Assessment

• Obtain a baseline chest X‑ray before initiating or continuing methotrexate in patients with ILD. 2
• Evaluate additional risk factors such as smoking status and age > 40 years. 2
• Counsel patients about their potentially increased risk of methotrexate pneumonitis before therapy starts. 2

Ongoing Monitoring

• Perform a clinical assessment for new or worsening respiratory symptoms at every clinic visit while the patient is on methotrexate. 2
• If respiratory symptoms arise, obtain a repeat chest X‑ray and arrange pulmonary referral promptly. 2

Methotrexate Use in Patients with Restrictive Lung Disease

Introduction to Methotrexate Therapy

• The American College of Rheumatology conditionally recommends methotrexate for patients with mild and stable airway or parenchymal lung disease, incidental disease detected on imaging, and moderate-to-high inflammatory arthritis disease activity 3, 4
• Methotrexate serves as an anchor treatment in rheumatoid arthritis with no alternatives offering similar efficacy and superior long-term safety profiles 3, 4

Patient Selection and Counseling

• Patients with preexisting lung disease must be informed of their potentially increased risk of methotrexate pneumonitis prior to treatment initiation 3, 4, 5
• Preexisting lung disease is a documented risk factor for methotrexate-related pneumonitis 3, 5

Baseline Assessment and Monitoring

• Before starting methotrexate in restrictive lung disease patients, document baseline respiratory symptoms, obtain chest X-ray, perform pulmonary function tests, and assess additional risk factors 4, 5, 6
• More frequent monitoring than standard methotrexate protocols is required, including clinical assessment for respiratory symptoms at every visit and laboratory monitoring 4, 5

Safety Measures and Drug Interactions

• Folic acid supplementation is strongly recommended to reduce toxicity, at least 5 mg per week (daily except methotrexate day) 4, 6
• Trimethoprim-sulfamethoxazole is absolutely contraindicated due to severe bone marrow suppression risk 7

Alternative Therapies

• The 2023 ACR/CHEST guideline conditionally recommends against methotrexate as first-line treatment for rheumatoid arthritis-associated interstitial lung disease 4
• Alternative DMARDs with potentially lower pulmonary risk include hydroxychloroquine, sulfasalazine, and biologic DMARDs (non-TNF inhibitors preferred if heart failure present) 3